Article2007

Efficacy and Safety of Topiramate Monotherapy in Civilian Posttraumatic Stress Disorder

Phebe M. Tucker · Richard P. Trautman · Dorothy B. Wyatt · Jamie Louise Thompson · Shu‐Chen Wu · Julie A. Capece +1 more

122 citations0/0 files storedThe Journal of Clinical Psychiatry

No readable copy stored yet — this record is metadata only.

No open-access location is known for this record yet.

Literature note Cite in a project Citation map

Posttraumatic Stress Disorder Research Sleep and related disorders Traumatic Brain Injury Research

Abstract

OBJECTIVE: This double-blind, placebo-controlled trial assessed efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder (PTSD). METHOD: Outpatients (18-64 years) with DSM-IV non-combat-related PTSD and Clinician-Administered PTSD Scale (CAPS) scores >or= 50 were eligible. Topiramate was started at 25 mg/day and titrated by 25-50 mg/week to 400 mg/day or maximum tolerated dose. Data were collected between April 26, 2002, and February 4, 2004. Primary efficacy, change in total CAPS score, and secondary efficacy measures were assessed by analysis of covariance in the intent-to-treat (ITT) population with last observation carried forward. RESULTS: The ITT population comprised 38 patients with mean +/- SD baseline total CAPS scores of 88.3 +/- 13.8 (topiramate, N = 19) and 91.1 +/- 13.7 (placebo, N = 19). Although a decrease in total CAPS score was noted (topiramate, -52.7; placebo, -42.0), this difference was not statistically significant (p = .232). Topiramate-treated patients exhibited significant reductions in reexperiencing symptoms (CAPS cluster B: topiramate, 74.9%; placebo, 50.2%; p = .038) and Treatment Outcome PTSD scale (topiramate, 68.0%; placebo, 41.6%; p = .025). Reductions approaching statistical significance, based on a nominal p value, were noted in mean total Clinical Global Impressions-Improvement Scale scores (topiramate, 1.9 +/- 1.2; placebo, 2.6 +/- 1.1; p = .055). CONCLUSION: These preliminary results suggest that further, adequately powered studies of topiramate for the treatment of civilian PTSD are warranted.

Paper brief

Loading…

Cite this work

Citation unavailable for this work.

BibTeX RIS CSL-JSON

No public copy is stored for this record, so only the metadata is cited.

Citations in this library

Citation map →

Stored only when both papers are in the corpus — 122 citations exist upstream.

References

1960A RATING SCALE FOR DEPRESSION 2003Development of a new resilience scale: The Connor-Davidson Resilience Scale (CD-RISC)1959THE ASSESSMENT OF ANXIETY STATES BY RATING 1995Posttraumatic Stress Disorder in the National Comorbidity Survey 1995Factor structure of the barratt impulsiveness scale 1995The development of a Clinician-Administered PTSD Scale 2001Clinician-administered PTSD scale: A review of the first ten years of research 1997Assessing Psychiatric Impairment in Primary Care with the Sheehan Disability Scale

Cited by

2010Psychopharmacologic Treatment of Posttraumatic Stress Disorder in Children and Adolescents 2009Guideline Watch (March 2009): Practice Guideline for the Treatment of Patients with Acute Stress Disorder and Posttraumatic Stress Disorder 2010Epidemiology and Management of Alcohol Dependence in Individuals with Post-Traumatic Stress Disorder 2012Pharmacotherapy for posttraumatic stress disorder: Review with clinical applications 2026Pharmacotherapy for post traumatic stress disorder (PTSD)

Explore the map →

Papers that cite the same references — the relational fallback while embeddings are still backfilling.

Imported from OpenAlex (CC0) — nothing here is generated.